Heated chemo & surgery combined with Direct-Abdominal immunotherapy in ovarian cancer trial
NCT ID NCT03959761
Summary
This study tested if it was safe to give an immunotherapy drug called nivolumab directly into the abdomen (intraperitoneal) after major surgery and heated chemotherapy (HIPEC) for advanced ovarian cancer. The main goal was to find the safest dose and see how well patients tolerated this combined approach. It involved 22 patients with recurrent ovarian cancer who were not eligible for standard first-line surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospices Civils de Lyon
Lyon, 69002, France
Conditions
Explore the condition pages connected to this study.